PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients

PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients Assessment of the Correlation Between Body Mass Index and Recurrence Among Zoladex Treated Prostate Cancer Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01020604

Acronym

PROTECT-Z

Enrollment

1376

Registered

2009-11-25

Start date

2009-11-30

Completion date

2013-03-31

Last updated

2013-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Prostate Cancer

Keywords

BMI, Prostate cancer, Recurrence

Brief summary

The reports on relationship of obesity and biochemical or clinical recurrence of prostate cancer are controversial. Several reports have shown that obesity is associated with increased risk of biochemical or clinical failure after radical prostatectomy. Other prospective studies have shown no adverse effect of obesity on long-term outcomes after prostatectomy. Limited reports are available on the impact of obesity on prostate cancer progression after radiotherapy. Primary: to assess percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy. Secondary: to determine the Quality of Life differences among normal and overweight or obese prostate cancer patients by a Quality of Life questionnaire

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically proven prostate cancer patients being on adjuvant Zoladex treatment after primary therapy or on adjuvant therapy without primary curative therapy

Exclusion criteria

-Prostate cancer patients refractory to hormonal therapy, not agreeing to participate, allergy against treatment

Design outcomes

Primary

Measure	Time frame
Percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy.	Every 3 months

Secondary

Measure	Time frame
Quality of Life differences among normal and overweight or obese prostate cancer patients by a Quality of Life questionnaire	Every 3 months

Countries

Hungary

Outcome results